1. <bdo id="5c7pj"><dfn id="5c7pj"><thead id="5c7pj"></thead></dfn></bdo>

      <bdo id="5c7pj"></bdo>

      中醫中藥

      小兒上呼吸道感染治療中應用喜炎平注射液的臨床價值

      馬琰

      [文章下載]

      【摘要】  【摘要】目的 分析小兒上呼吸道感染治療中應用喜炎平注射液的臨床價值。方法 選取2016年3月至2019年12月本院收治的102例小兒上呼吸道感染患兒,根據不同治療方案將其分成兩組各51例,對照組采用利巴韋林注射液[10 mg/(kg?d),配以5%葡萄糖溶液250 mL,靜脈滴注,qd]治療,觀察組在此基礎上采用喜炎平注射液[5 mg/(kg?d),配以5%葡萄糖溶液250 mL,靜脈滴注,qd]治療,7 d后比較兩組患兒的癥狀消失時間和臨床療效,統計不良反應發生情況。

      【關鍵字】  上呼吸道感染,喜炎平,安全性

      中圖分類號:文獻標識碼:文章編號:

      [Abstract]Objective To analyze the clinical value of Xiyanping injection in the treatment of upper respiratory tract infection in children. Methods A total of 102 children with upper respiratory tract infection admitted to our hospital from March 2016 to December 2019 were enrolled in this study. According to different treatment protocols, 51 patients were divided into two groups. The control group was treated with ribavirin injection [10 mg/(kg?d), with 250 mL of 5% glucose solution, intravenous drip, qd] treatment, the observation group on this basis using Xiyanping injection [5 mg/(kg?d), with 5% glucose solution 250 mL Intravenous infusion, qd] treatment, 7 days after the two groups of children with symptom disappearance time and clinical efficacy, statistical adverse reactions occurred. Results The disappearance time, disappearance time of cough and disappearance of nasal obstruction were significantly shorter in the observation group than in the control group (P<0.05). The effective rate of treatment in the observation group (96.08%) was significantly higher than that in the control group (80.39%). P<0.05); the incidence of adverse reactions in the observation group (5.88%), and the control group (9.80%), there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The application of Xiyanping injection in the treatment of upper respiratory tract infection in children can effectively shorten the disappearance of symptoms in children, improve clinical efficacy, and be safe and reliable.

      上呼吸道感染是兒科高發呼吸道疾病類型之一,主要由病毒、支原體、細菌感染引發所致,具有發病率高、起病急、進展迅速的特點[1-2]。臨床中兒科上呼吸道感染發生率約為28%,患者主要表現為咳嗽、鼻塞流涕、發熱、惡心嘔吐、厭食等癥狀,多采用抗病毒療法治療患兒[3-4]。由于抗病毒類藥物具有明顯的副作用,部分患兒用藥后會產生耐藥性,影響小兒身心健康,因此有必要研究科學的治療路徑[5-6]。為了探討更加高效、合理的治療方案,本文就小兒上呼吸道感染治療中應用喜炎平注射液的臨床價值展開了下述分析。 1 資料與方法 1.1 一般資料:選取本院2016年3月至2019年12月收治的小兒上呼吸道感染患兒102例。納入標準:①符合上呼吸道感染的診斷標準[7],伴有流涕、咳嗽、發熱、聲音嘶啞等癥狀,體溫>38.0 ℃,血常規提示外周血白細胞計數正常;②病程<5 d;③患兒家屬同意配合研究。排除標準:①器質性功能障礙;②藥物過敏;③造血系統疾??;④免疫系統疾??;⑤臨床資料缺失。根據不同治療方案將其分成兩組,每組51例,觀察組男27例,女24例;年齡1~8歲,平均(3.28±0.39)歲。對照組男26例,女25例;年齡1~7歲,平均(3.42±0.41)歲?;純杭覍倬咧闄?,組間基線數據對比均衡性良好。 1.2 方法:給予全部患兒退熱、止咳、抗菌、糾正水電解質紊亂等對癥治療。在此前提下,對照組予以利巴韋林注射液(齊魯制藥有限公司,國藥準字H19993274)10 mg/(kg?d),配以5%葡萄糖溶液250 mL,靜脈滴注,1次/天。觀察組在上述基礎上予以喜炎平注射液(江西青峰藥業有限公司,國藥準字Z20026249)5 mg/(kg?d),配以5%葡萄糖溶液250mL,靜脈滴注,1次/天。兩組患兒均治療7 d。 1.3 觀察指標:①比較兩組的發熱消失時間、咳嗽消失時間、鼻塞流涕消失時間。②根據《中藥新藥臨床研究指導原則》[8]評價癥候積分,包括發熱、咳嗽、咽痛、鼻塞流涕,采用4級評分法評為0~3分,評分越高表明患兒病情越嚴重,以此為依據評價療效:①無效:治療后癥狀、體征均無明顯改善,或病情加重,減分率<30%;②有效:癥狀、體征好轉,減分率30%~69%;③顯效:癥狀及體征明顯改善,減分率70%~94%;④治愈:臨床癥狀、體征消失消失,減分率≥95%,減分率=(治療前臨床癥狀積分-治療后臨床癥狀積分)/治療前臨床癥狀積分×100%,治療有效率=(①+②+③)/51×100%。(3)統計不良反應發生情況,包括皮疹、惡心嘔吐、白細胞減少。 1.4 統計學方法:將102例小兒上呼吸道感染患兒的臨床數據輸入SPSS23.0運行處理,以χ2檢驗療效等無序分類資料(%、n),以t檢驗肺功能指標等數值變量資料( ),P<0.05,提示有差異。

      友情鏈接

      女人ZOZOZO禽交